

Please note: translation is provided for informational purposes only.

**UPDATE TO THE DECLARATION OF COMPLIANCE DATED OCTOBER 2022
WITH THE GERMAN CORPORATE GOVERNANCE CODE PURSUANT TO SECTION 161 PARAGRAPH 1
OF THE GERMAN STOCK CORPORATION ACT (AKTG)**

.....

The Executive Board and the Supervisory Board of Epigenomics AG have issued their last Declaration of Compliance in October 2022. Due to an additional deviation from the recommendations under the German Corporate Governance Code (the "Code") in its version of April 28, 2022 (published by the Ministry of Justice in the official part of the Federal Gazette on June 27, 2022), the following update of the Declaration of Compliance dated October 2022 has become necessary:

Recommendation F.2

Due to strategic and operational reasons related to the restructuring announced by the Company on February 15, 2023 the Consolidated Financial Statements for the financial year 2022 will be published only on April 21, 2023. Accordingly, in deviation from recommendation F.2 of the Code, the Consolidated Financial Statements for the financial year 2022 will not be made publicly accessible within 90 days of the end of the financial year. Regarding future financial years the Company will again comply with the recommendation F.2 of the Code.

Berlin, February 2023

On behalf of the Supervisory Board:

Dr. Helge Lubenow
(Chairwoman of the Supervisory Board)

On behalf of the Executive Board:

Gregory K. Hamilton
(CEO)

Andrew Lukowiak
(CSO)

Jens Ravens
(CFO)